KA/EN
Register
Medicines reference
Search
Search
Product

Biseptol

Favourites

Trimethoprim/Sulfonamide · Adamed, Medana Pharma (Terpol Group)

3 forms: suspension, tablet. In force in Georgia: 2 of 3 (human register).

Forms and doses2 of 3 in force in Georgia

Form Dose Frequency Georgia
120 mg (100 mg + 20 mg), Tablet No label dose in the reference yet - Georgia Yes, human
In force until 01 Nov 2029
Human (Ministry of Health, RAMA)
№ რ-041281, რ-042300
Verified on: 15 Oct 2026
Details: pack, label wording, sources, registration

Biseptol 120 mg (100 mg + 20 mg), Tablet

tablet, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Off-label oral trimethoprim-sulfamethoxazole for susceptible bacterial infections and selected protozoal disease in dogs, after diagnosis and culture/susceptibility testing when applicable
6.3/10
Situational / acceptable
vetman assessment

Biseptol

120 mg (100 mg + 20 mg), tablet, human medicine
Assessed clinical scopeDog · Off-label oral trimethoprim-sulfamethoxazole for susceptible bacterial infections and selected protozoal disease in dogs, after diagnosis and culture/susceptibility testing when applicable · By mouth
Care settingVeterinary-prescribed home or hospital oral treatment with hydration, diagnosis-specific duration and monitoring matched to course length
vetman score 6.3/10 Situational / acceptable
Evidence confidence: Medium Georgia: Yes, human · № რ-041281, რ-042300 · Verified on 15 Oct 2026 Off-label use

The active combination has a legitimate stewardship role, but this human tablet gives coarse veterinary dose increments. Use only when a safe accurate dose can be delivered and the target is susceptible.

Regulatory and scientific credibility6.5/10

The exact human tablet is currently registered in Georgia and the EU with a public Polish SPC, but veterinary use is off-label. Veterinary labels and current guidelines support the active combination, not this exact product.

Clinical efficacy7.0/10

Current UTI and pyoderma guidance supports potentiated sulfonamides for selected susceptible infections; an 84-dog UTI study and modern eight-dog TMP-SMX PK study add direct support. Evidence is uneven across the broad antimicrobial and antiprotozoal scope, so culture and diagnosis remain decisive.

Safety and tolerability6.0/10

A 2026 systematic review estimated mild adverse events at 2.3% and severe events at 0.2% in dogs, but KCS, immune polyarthritis, hepatopathy and blood dyscrasias can be serious and are more often reported after courses longer than seven days.

Clinical practicality5.0/10

The whole-only 120 mg tablet corresponds to an 8 kg step at 15 mg/kg. Crushing permits compounding but not accurate casual division, so many dogs need a validated liquid preparation.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use with sulfonamide/trimethoprim hypersensitivity, severe hepatic or renal dysfunction, or blood dyscrasia.
  • Avoid with reduced water intake or fluid loss; maintain adequate hydration to reduce crystalluria and renal injury.
  • Dogs can rarely develop KCS, immune polyarthritis, hepatopathy, skin reactions or blood dyscrasias; stop and assess promptly if compatible signs appear.
  • For courses longer than seven days, monitor CBC and organ function; in dogs obtain baseline and periodic Schirmer tear tests.
  • Safety in pregnancy and lactation is not established; use only after an individual benefit-risk assessment.
  • Review methotrexate, folate antagonists, anticoagulants, phenytoin and other highly protein-bound medicines before use.
  • AMEG Category D/Prudence: treat only a clinically indicated susceptible target; obtain culture and susceptibility where applicable and avoid unnecessary duration.
  • Do not assume anaerobic respiratory coverage; Enterococcus is intrinsically resistant and broad label claims do not replace diagnosis.
  • Calculate the dose from the combined trimethoprim plus sulfamethoxazole amount; do not substitute sulfadiazine strength calculations without recalculation.
Assessment sources
  1. Georgia human register2026
  2. VMD SPC 20262026
  3. EMA AMEG D2023
  4. ISCAID urinary guideline 20192019
  5. ISCAID 20172017
  6. TMS safety review 20262026
  7. ISCAID 20252025
  8. TMP-SMX dog PK 20262026
  9. Canine UTI study 19791979
  10. Polish Biseptol SPC2025
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Off-label oral trimethoprim-sulfamethoxazole for susceptible bacterial infections and selected protozoal disease in cats, after diagnosis and culture/susceptibility testing when applicable
5.8/10
Weak evidence support
vetman assessment

Biseptol

120 mg (100 mg + 20 mg), tablet, human medicine
Assessed clinical scopeCat · Off-label oral trimethoprim-sulfamethoxazole for susceptible bacterial infections and selected protozoal disease in cats, after diagnosis and culture/susceptibility testing when applicable · By mouth
Care settingVeterinary-prescribed home or hospital oral treatment with hydration, diagnosis-specific duration and monitoring matched to course length
vetman score 5.8/10 Weak evidence support
Evidence confidence: Medium Georgia: Yes, human · № რ-041281, რ-042300 · Verified on 15 Oct 2026 Off-label use

The active combination has a legitimate stewardship role, but this human tablet gives coarse veterinary dose increments. Use only when a safe accurate dose can be delivered and the target is susceptible.

Regulatory and scientific credibility6.5/10

The exact human tablet is currently registered in Georgia and the EU with a public Polish SPC, but veterinary use is off-label. Veterinary labels and current guidelines support the active combination, not this exact product.

Clinical efficacy6.5/10

UTI and feline lower-urinary-tract guidance recognises trimethoprim-sulfonamide as a first-line option when antimicrobial treatment is truly indicated, but direct feline clinical and PK evidence for oral TMP-SMX is limited and Enterococcus is intrinsically resistant.

Safety and tolerability6.0/10

Comparative evidence does not show a large overall excess of adverse events, but feline safety data are much thinner than canine data. Gastrointestinal effects, hypersensitivity, crystalluria and haematologic or hepatic injury require selection, hydration and monitoring.

Clinical practicality3.0/10

A typical 4 kg cat needs about 60 mg, half of this whole-only tablet. Accurate use therefore requires validated compounding rather than informal splitting.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use with sulfonamide/trimethoprim hypersensitivity, severe hepatic or renal dysfunction, or blood dyscrasia.
  • Avoid with reduced water intake or fluid loss; maintain adequate hydration to reduce crystalluria and renal injury.
  • Direct feline safety evidence is limited; stop and assess vomiting, diarrhoea, rash, jaundice, fever, pallor or urinary signs promptly.
  • For courses longer than seven days, monitor CBC and organ function; in dogs obtain baseline and periodic Schirmer tear tests.
  • Safety in pregnancy and lactation is not established; use only after an individual benefit-risk assessment.
  • Review methotrexate, folate antagonists, anticoagulants, phenytoin and other highly protein-bound medicines before use.
  • AMEG Category D/Prudence: treat only a clinically indicated susceptible target; obtain culture and susceptibility where applicable and avoid unnecessary duration.
  • Do not assume anaerobic respiratory coverage; Enterococcus is intrinsically resistant and broad label claims do not replace diagnosis.
  • Calculate the dose from the combined trimethoprim plus sulfamethoxazole amount; do not substitute sulfadiazine strength calculations without recalculation.
Assessment sources
  1. Georgia human register2026
  2. VMD SPC 20262026
  3. EMA AMEG D2023
  4. ISCAID urinary guideline 20192019
  5. ISCAID 20172017
  6. TMS safety review 20262026
  7. iCatCare LUTD 20252025
  8. Polish Biseptol SPC2025
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Trimethoprim/Sulfonamide120 mg
Formulation Type
Tablet
Administration route
By mouth
Manufacturer
Adamed · Poland
Registration
Georgia Yes, human
In force until 01 Nov 2029
Human (Ministry of Health, RAMA)
№ რ-041281, რ-042300
Verified on: 15 Oct 2026
 EU Yes, human
Verified on: 16 Oct 2026
 UK No
Verified on: 16 Oct 2026
 US No
Verified on: 16 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
240 mg/5 ml (200 mg + 40 mg), Suspension No label dose in the reference yet - Georgia No longer listed
Was registered; not in the current register
Human (Ministry of Health, RAMA)
In the register: ბისეპტოლი 240მგ/5მლ სუსპენზია
№ რ-019169
Verified on: 22 Oct 2026
Details: pack, label wording, sources, registration

Biseptol 240 mg/5 ml (200 mg + 40 mg), Suspension

oral suspension, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Off-label oral trimethoprim-sulfamethoxazole for susceptible bacterial infections and selected protozoal disease in dogs, after diagnosis and culture/susceptibility testing when applicable
6.6/10
Situational / acceptable
vetman assessment

Biseptol

240 mg/5 ml (200 mg + 40 mg), oral suspension, human medicine
Assessed clinical scopeDog · Off-label oral trimethoprim-sulfamethoxazole for susceptible bacterial infections and selected protozoal disease in dogs, after diagnosis and culture/susceptibility testing when applicable · By mouth
Care settingVeterinary-prescribed home or hospital oral treatment with hydration, diagnosis-specific duration and monitoring matched to course length
vetman score 6.6/10 Situational / acceptable
Evidence confidence: Medium Georgia: No longer listed · № რ-019169 · Verified on 22 Oct 2026 Off-label use

The liquid is the clinically workable Biseptol form for weight-based veterinary dosing, but use remains off-label and must be tied to a susceptible target, hydration and course-appropriate monitoring.

Regulatory and scientific credibility6.0/10

The exact human suspension has a current Polish/EU SPC, but its Georgian certificate expired in May 2026 and veterinary use is off-label. Veterinary labels and current guidelines support the active combination, not this exact product.

Clinical efficacy7.0/10

Current UTI and pyoderma guidance supports potentiated sulfonamides for selected susceptible infections; an 84-dog UTI study and modern eight-dog TMP-SMX PK study add direct support. Evidence is uneven across the broad antimicrobial and antiprotozoal scope, so culture and diagnosis remain decisive.

Safety and tolerability6.0/10

A 2026 systematic review estimated mild adverse events at 2.3% and severe events at 0.2% in dogs, but KCS, immune polyarthritis, hepatopathy and blood dyscrasias can be serious and are more often reported after courses longer than seven days.

Clinical practicality8.0/10

The 48 mg/ml suspension permits weight-based measurement (about 0.3125 ml/kg at 15 mg/kg) and is the most workable presentation; shaking, calibrated oral measurement and palatability still matter.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use with sulfonamide/trimethoprim hypersensitivity, severe hepatic or renal dysfunction, or blood dyscrasia.
  • Avoid with reduced water intake or fluid loss; maintain adequate hydration to reduce crystalluria and renal injury.
  • Dogs can rarely develop KCS, immune polyarthritis, hepatopathy, skin reactions or blood dyscrasias; stop and assess promptly if compatible signs appear.
  • For courses longer than seven days, monitor CBC and organ function; in dogs obtain baseline and periodic Schirmer tear tests.
  • Safety in pregnancy and lactation is not established; use only after an individual benefit-risk assessment.
  • Review methotrexate, folate antagonists, anticoagulants, phenytoin and other highly protein-bound medicines before use.
  • AMEG Category D/Prudence: treat only a clinically indicated susceptible target; obtain culture and susceptibility where applicable and avoid unnecessary duration.
  • Do not assume anaerobic respiratory coverage; Enterococcus is intrinsically resistant and broad label claims do not replace diagnosis.
  • Calculate the dose from the combined trimethoprim plus sulfamethoxazole amount; do not substitute sulfadiazine strength calculations without recalculation.
Assessment sources
  1. Georgia human register2026
  2. VMD SPC 20262026
  3. EMA AMEG D2023
  4. ISCAID urinary guideline 20192019
  5. ISCAID 20172017
  6. TMS safety review 20262026
  7. ISCAID 20252025
  8. TMP-SMX dog PK 20262026
  9. Canine UTI study 19791979
  10. Polish Biseptol suspension SPC2025
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Off-label oral trimethoprim-sulfamethoxazole for susceptible bacterial infections and selected protozoal disease in cats, after diagnosis and culture/susceptibility testing when applicable
6.4/10
Situational / acceptable
vetman assessment

Biseptol

240 mg/5 ml (200 mg + 40 mg), oral suspension, human medicine
Assessed clinical scopeCat · Off-label oral trimethoprim-sulfamethoxazole for susceptible bacterial infections and selected protozoal disease in cats, after diagnosis and culture/susceptibility testing when applicable · By mouth
Care settingVeterinary-prescribed home or hospital oral treatment with hydration, diagnosis-specific duration and monitoring matched to course length
vetman score 6.4/10 Situational / acceptable
Evidence confidence: Medium Georgia: No longer listed · № რ-019169 · Verified on 22 Oct 2026 Off-label use

The liquid is the clinically workable Biseptol form for weight-based veterinary dosing, but use remains off-label and must be tied to a susceptible target, hydration and course-appropriate monitoring.

Regulatory and scientific credibility6.0/10

The exact human suspension has a current Polish/EU SPC, but its Georgian certificate expired in May 2026 and veterinary use is off-label. Veterinary labels and current guidelines support the active combination, not this exact product.

Clinical efficacy6.5/10

UTI and feline lower-urinary-tract guidance recognises trimethoprim-sulfonamide as a first-line option when antimicrobial treatment is truly indicated, but direct feline clinical and PK evidence for oral TMP-SMX is limited and Enterococcus is intrinsically resistant.

Safety and tolerability6.0/10

Comparative evidence does not show a large overall excess of adverse events, but feline safety data are much thinner than canine data. Gastrointestinal effects, hypersensitivity, crystalluria and haematologic or hepatic injury require selection, hydration and monitoring.

Clinical practicality7.5/10

The 48 mg/ml suspension permits weight-based measurement (about 0.3125 ml/kg at 15 mg/kg) and is the most workable presentation; shaking, calibrated oral measurement and palatability still matter.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use with sulfonamide/trimethoprim hypersensitivity, severe hepatic or renal dysfunction, or blood dyscrasia.
  • Avoid with reduced water intake or fluid loss; maintain adequate hydration to reduce crystalluria and renal injury.
  • Direct feline safety evidence is limited; stop and assess vomiting, diarrhoea, rash, jaundice, fever, pallor or urinary signs promptly.
  • For courses longer than seven days, monitor CBC and organ function; in dogs obtain baseline and periodic Schirmer tear tests.
  • Safety in pregnancy and lactation is not established; use only after an individual benefit-risk assessment.
  • Review methotrexate, folate antagonists, anticoagulants, phenytoin and other highly protein-bound medicines before use.
  • AMEG Category D/Prudence: treat only a clinically indicated susceptible target; obtain culture and susceptibility where applicable and avoid unnecessary duration.
  • Do not assume anaerobic respiratory coverage; Enterococcus is intrinsically resistant and broad label claims do not replace diagnosis.
  • Calculate the dose from the combined trimethoprim plus sulfamethoxazole amount; do not substitute sulfadiazine strength calculations without recalculation.
Assessment sources
  1. Georgia human register2026
  2. VMD SPC 20262026
  3. EMA AMEG D2023
  4. ISCAID urinary guideline 20192019
  5. ISCAID 20172017
  6. TMS safety review 20262026
  7. iCatCare LUTD 20252025
  8. Polish Biseptol suspension SPC2025
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Trimethoprim/Sulfonamide48 mg/ml
Formulation Type
Suspension
Administration route
By mouth
Registration
Georgia No longer listed
Was registered; not in the current register
Human (Ministry of Health, RAMA)
In the register: ბისეპტოლი 240მგ/5მლ სუსპენზია
№ რ-019169
Verified on: 22 Oct 2026
 EU Yes, human
Verified on: 16 Oct 2026
 UK No
Verified on: 16 Oct 2026
 US No
Verified on: 16 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
480 mg (400 mg + 80 mg), Tablet No label dose in the reference yet - Georgia Yes, human
In force until 15 Jul 2029
Human (Ministry of Health, RAMA)
№ რ-041280, რ-041565
Verified on: 15 Oct 2026
Details: pack, label wording, sources, registration

Biseptol 480 mg (400 mg + 80 mg), Tablet

tablet, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Off-label oral trimethoprim-sulfamethoxazole for susceptible bacterial infections and selected protozoal disease in dogs, after diagnosis and culture/susceptibility testing when applicable
6.1/10
Situational / acceptable
vetman assessment

Biseptol

480 mg (400 mg + 80 mg), tablet, human medicine
Assessed clinical scopeDog · Off-label oral trimethoprim-sulfamethoxazole for susceptible bacterial infections and selected protozoal disease in dogs, after diagnosis and culture/susceptibility testing when applicable · By mouth
Care settingVeterinary-prescribed home or hospital oral treatment with hydration, diagnosis-specific duration and monitoring matched to course length
vetman score 6.1/10 Situational / acceptable
Evidence confidence: Medium Georgia: Yes, human · № რ-041280, რ-041565 · Verified on 15 Oct 2026 Off-label use

The active combination has a legitimate stewardship role, but this human tablet gives coarse veterinary dose increments. Use only when a safe accurate dose can be delivered and the target is susceptible.

Regulatory and scientific credibility6.5/10

The exact human tablet is currently registered in Georgia and the EU with a public Polish SPC, but veterinary use is off-label. Veterinary labels and current guidelines support the active combination, not this exact product.

Clinical efficacy7.0/10

Current UTI and pyoderma guidance supports potentiated sulfonamides for selected susceptible infections; an 84-dog UTI study and modern eight-dog TMP-SMX PK study add direct support. Evidence is uneven across the broad antimicrobial and antiprotozoal scope, so culture and diagnosis remain decisive.

Safety and tolerability6.0/10

A 2026 systematic review estimated mild adverse events at 2.3% and severe events at 0.2% in dogs, but KCS, immune polyarthritis, hepatopathy and blood dyscrasias can be serious and are more often reported after courses longer than seven days.

Clinical practicality4.0/10

The scored 480 mg tablet permits only 240 mg steps, equivalent to 16 kg at the common 15 mg/kg dose; smaller or intermediate dogs need a validated compounded alternative.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use with sulfonamide/trimethoprim hypersensitivity, severe hepatic or renal dysfunction, or blood dyscrasia.
  • Avoid with reduced water intake or fluid loss; maintain adequate hydration to reduce crystalluria and renal injury.
  • Dogs can rarely develop KCS, immune polyarthritis, hepatopathy, skin reactions or blood dyscrasias; stop and assess promptly if compatible signs appear.
  • For courses longer than seven days, monitor CBC and organ function; in dogs obtain baseline and periodic Schirmer tear tests.
  • Safety in pregnancy and lactation is not established; use only after an individual benefit-risk assessment.
  • Review methotrexate, folate antagonists, anticoagulants, phenytoin and other highly protein-bound medicines before use.
  • AMEG Category D/Prudence: treat only a clinically indicated susceptible target; obtain culture and susceptibility where applicable and avoid unnecessary duration.
  • Do not assume anaerobic respiratory coverage; Enterococcus is intrinsically resistant and broad label claims do not replace diagnosis.
  • Calculate the dose from the combined trimethoprim plus sulfamethoxazole amount; do not substitute sulfadiazine strength calculations without recalculation.
Assessment sources
  1. Georgia human register2026
  2. VMD SPC 20262026
  3. EMA AMEG D2023
  4. ISCAID urinary guideline 20192019
  5. ISCAID 20172017
  6. TMS safety review 20262026
  7. ISCAID 20252025
  8. TMP-SMX dog PK 20262026
  9. Canine UTI study 19791979
  10. Polish Biseptol SPC2025
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Off-label oral trimethoprim-sulfamethoxazole for susceptible bacterial infections and selected protozoal disease in cats, after diagnosis and culture/susceptibility testing when applicable
5.5/10
Weak evidence support
vetman assessment

Biseptol

480 mg (400 mg + 80 mg), tablet, human medicine
Assessed clinical scopeCat · Off-label oral trimethoprim-sulfamethoxazole for susceptible bacterial infections and selected protozoal disease in cats, after diagnosis and culture/susceptibility testing when applicable · By mouth
Care settingVeterinary-prescribed home or hospital oral treatment with hydration, diagnosis-specific duration and monitoring matched to course length
vetman score 5.5/10 Weak evidence support
Evidence confidence: Medium Georgia: Yes, human · № რ-041280, რ-041565 · Verified on 15 Oct 2026 Off-label use

The active combination has a legitimate stewardship role, but this human tablet gives coarse veterinary dose increments. Use only when a safe accurate dose can be delivered and the target is susceptible.

Regulatory and scientific credibility6.5/10

The exact human tablet is currently registered in Georgia and the EU with a public Polish SPC, but veterinary use is off-label. Veterinary labels and current guidelines support the active combination, not this exact product.

Clinical efficacy6.5/10

UTI and feline lower-urinary-tract guidance recognises trimethoprim-sulfonamide as a first-line option when antimicrobial treatment is truly indicated, but direct feline clinical and PK evidence for oral TMP-SMX is limited and Enterococcus is intrinsically resistant.

Safety and tolerability6.0/10

Comparative evidence does not show a large overall excess of adverse events, but feline safety data are much thinner than canine data. Gastrointestinal effects, hypersensitivity, crystalluria and haematologic or hepatic injury require selection, hydration and monitoring.

Clinical practicality1.5/10

A typical 4 kg cat needs about 60 mg at 15 mg/kg, one eighth of this tablet; the tablet is validated only for halves, so accurate direct dosing is not feasible.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use with sulfonamide/trimethoprim hypersensitivity, severe hepatic or renal dysfunction, or blood dyscrasia.
  • Avoid with reduced water intake or fluid loss; maintain adequate hydration to reduce crystalluria and renal injury.
  • Direct feline safety evidence is limited; stop and assess vomiting, diarrhoea, rash, jaundice, fever, pallor or urinary signs promptly.
  • For courses longer than seven days, monitor CBC and organ function; in dogs obtain baseline and periodic Schirmer tear tests.
  • Safety in pregnancy and lactation is not established; use only after an individual benefit-risk assessment.
  • Review methotrexate, folate antagonists, anticoagulants, phenytoin and other highly protein-bound medicines before use.
  • AMEG Category D/Prudence: treat only a clinically indicated susceptible target; obtain culture and susceptibility where applicable and avoid unnecessary duration.
  • Do not assume anaerobic respiratory coverage; Enterococcus is intrinsically resistant and broad label claims do not replace diagnosis.
  • Calculate the dose from the combined trimethoprim plus sulfamethoxazole amount; do not substitute sulfadiazine strength calculations without recalculation.
Assessment sources
  1. Georgia human register2026
  2. VMD SPC 20262026
  3. EMA AMEG D2023
  4. ISCAID urinary guideline 20192019
  5. ISCAID 20172017
  6. TMS safety review 20262026
  7. iCatCare LUTD 20252025
  8. Polish Biseptol SPC2025
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Trimethoprim/Sulfonamide480 mg
Formulation Type
Tablet
Administration route
By mouth
Manufacturer
Adamed · Poland
Registration
Georgia Yes, human
In force until 15 Jul 2029
Human (Ministry of Health, RAMA)
№ რ-041280, რ-041565
Verified on: 15 Oct 2026
 EU Yes, human
Verified on: 16 Oct 2026
 UK No
Verified on: 16 Oct 2026
 US No
Verified on: 16 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Active substance doses, with sources

Each dose comes with its source. Check the label of the product you use.

Active substance Trimethoprim/Sulfonamide
Dose calculatorCalculates the active-substance amount; it is not a prescription.
PatientSpecies and weight will be filled in automatically in other calculators.
Selected dose
Dose Species Indication Route Frequency Source
15 mg/kg Dog, Cat Bacterial Infection; Skin and Soft Tissue Infection; Respiratory Tract Infection By mouth 2 times daily
VMD SPC 2026
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Trisulfin vet. 25 mg/125 mg chewable tablets for dogs and cats - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2026
ISCAID 2025
Guideline or consensus statement
Recommendations agreed by a panel of veterinary specialists after reviewing the evidence. They guide practice and do not authorise a product.
Antimicrobial use guidelines for canine pyoderma by the International Society for Companion Animal Infectious Diseases (ISCAID)
Veterinary Dermatology, 2025
ISCAID 2017
Guideline or consensus statement
Recommendations agreed by a panel of veterinary specialists after reviewing the evidence. They guide practice and do not authorise a product.
Antimicrobial Use Guidelines for Treatment of Respiratory Tract Disease in Dogs and Cats
Journal of Veterinary Internal Medicine, 2017
30 mg/kg Dog Bacterial Infection By mouth once daily
MSD Vet Manual 2026
Reference book
A veterinary reference written and reviewed by specialists, summarising accepted practice. The product label gives the authorised dose.
Sulfonamides and Sulfonamide Combinations Use in Animals
MSD/Merck Veterinary Manual, 2026
30–45 mg/kg
off-label
 Dog Bacterial Infection By mouth 2 times daily
MSD Vet Manual 2026
Reference book
A veterinary reference written and reviewed by specialists, summarising accepted practice. The product label gives the authorised dose.
Sulfonamides and Sulfonamide Combinations Use in Animals
MSD/Merck Veterinary Manual, 2026
30 mg/kg Dog, Cat Bacterial Infection Subcutaneous once daily
VMD SPC 2024
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Diatrim 200 mg/ml + 40 mg/ml solution for injection for cattle, pigs, dogs and cats - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2024

Known Contraindications

  • Critical
    Do not use in cases of hypersensitivity to the active substances (or any other sulfonamide)
    Sources: VMD SPC · VMD
  • Critical
    Do not use in case of severe liver or kidney insufficiency or blood dyscrasia. Do not use in animals with severe liver or renal damage
    Sources: VMD SPC · VMD
  • Critical
    Do not use in case of severe liver or kidney insufficiency or blood dyscrasia.
    Sources: VMD SPC · VMD
  • Critical
    Do not use in case of... blood dyscrasia
    Sources: VMD SPC · VMD
  • Critical
    Do not use trimethoprim/sulfonamide combinations when water intake is reduced or body-fluid loss is present. Maintain adequate hydration during treatment to reduce crystalluria and renal injury.
  • Warning
    Safety during pregnancy and lactation has not been established. Long-term exposure produced fetotoxic effects in laboratory mice; use only after an individual benefit-risk assessment.
  • Warning
    Safety during lactation has not been established. Use only after an individual benefit-risk assessment.
  • Warning (Dog)
    Trimethoprim/sulfonamide treatment can cause keratoconjunctivitis sicca in dogs, particularly during courses longer than 7 days. Perform a baseline Schirmer tear test, repeat it periodically, and stop promptly if tear production falls or ocular discharge develops.
    Sources: ISCAID
  • Warning (Dog)
    Dogs are particularly susceptible to idiosyncratic sulfonamide reactions, including fever, blood dyscrasias, polyarthropathy, skin eruptions, acute hepatopathy, and proteinuria. A breed-associated risk has been proposed in Dobermans, but the evidence is uncertain.
    Sources: ISCAID
  • Caution
    During prolonged trimethoprim/sulfonamide treatment, perform periodic haematology and monitor thyroid function when clinically indicated. High doses can cause reversible hypothyroidism in dogs.
    Sources: ISCAID · MSD Vet Manual

Known Drug Interactions

  • Minor warning Trimethoprim/Sulfonamide + Ganciclovir
    Although systemic exposure after ophthalmic ganciclovir is low, an interaction with trimethoprim/sulfonamide combinations cannot be excluded; additive bone-marrow toxicity is possible.
    Recommendation: Systemic absorption from the eye gel is low; perform haematology monitoring during prolonged combination therapy.
    Sources: Virgan SmPC
  • Minor warning Trimethoprim/Sulfonamide + Procaine Benzylpenicillin
    Procaine (in procaine benzylpenicillin) is an ester of para-aminobenzoic acid (PABA). Like other PABA-ester local anaesthetics such as tetracaine, it can reduce the effect of potentiated sulfonamides, at least locally.
    Recommendation: Account for a reduced sulfonamide effect during concomitant administration.
    Sources: MSD Vet Manual
  • Minor warning Amoxicillin + Trimethoprim/Sulfonamide
    Concurrent use of bactericidal beta-lactam antibiotics and bacteriostatic antimicrobials such as sulfonamides is generally not recommended because their effects may be antagonistic.
    Recommendation: Avoid concomitant administration.

Products are connected by name, active ingredients, or therapeutic group. They are not direct substitutes for one another.

Show all related products (59 more) Hide additional products

Same therapeutic group 59

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 22 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗